Paper - WANFANG MED ONLINE

You Position: Home > Paper

Controlling arachidonic acid metabolic network:from single-to multi-target inhibitors of key enzymes

( views:35, downloads:0 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 3

DOI:: 10.3321/j.issn:0513-4870.2009.03.004

Key Word:: 花生四烯酸代谢网络;关键酶;单靶标抑制剂;多靶标抑制剂

Abstract：炎症引发的疾病是人类常见的免疫系统疾病,医药市场对抗炎药物的需求量极大.花生四烯酸代谢网络是产生炎症介质的主要网络,网络中的一些蛋白质已成为抗炎药物设计的重要靶标,但这些单靶标药物不能很好地控制网络的平衡,同时容易引起副作用.大多数炎症引发的疾病是由多级联炎症代谢共同影响的结果,为了更好地治疗这类由多个药靶参与调控的复杂疾病,发展针对花生四烯酸代谢网络的多靶标药物具有迫切性.本文综述花生四烯酸代谢网络的关键靶标(如磷脂酶A2、环氧合酶、5-脂氧合酶和白三烯A4水解酶等)的特异性抑制剂和多靶标抑制剂研究进展.

Reference

[1]Yamada K,Seno K,Ueno M,etc.Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone.[J].2002,363(Pt.3).
[2]D K, Miller,J W, Gillard,P J, Vickers,etc.Identification and isolation of a membrane protein necessary for leukotriene production.[J].1990,343(6255).
[3]T, Shimizu,O, R?dmark,B, Samuelsson.Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid.[J].1984,81.
[4]Wong EH,Nikam SS,Shahid M.Multi- and single-target agents for major psychiatric diseases: Therapeutic opportunities and challenges.[J].2008,9(1).
[5]Rita Banzi,Manuela Bartolini,Maria Laura Bolognesi.Novel Class of Quinone-Bearing Polyamines as Multi-Target-Directed Ligands To Combat Alzheimer's Disease[J].2007,50(20).
[6]Sun-Shin Cha,Dennis Lee,Jerry Adams,etc.High-Resolution X-ray Crystallography Reveals Precise Binding Interactions between Human Nonpancreatic Secreted Phospholipase A<sub>2</sub> and a Highly Potent Inhibitor (FPL67047XX)[J].1996,39(20).
[7]T D, Penning.Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents.[J].2001,7(3).
[8]Leger S,Ouellet M,Guay J,etc.The discovery of rofecoxib, (MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), an orally active cyclooxygenase-2-inhibitor.[J].1999,9(13).
[9]S A, Beers,E A, Malloy,W, Wu,etc.N-(5-substituted) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase.[J].1997,5(4).
[10]Khanna D,Khanna PP,Furst DE.COX-2 controversy: where are we and where do we go from here?[J].2005,13(4).
[11]Meyer MC,Rastogi P,McHowat J,etc.Phospholipase A2 inhibitors as potential anti-inflammatory agents.[J].2005,11(10).
[12]Chung S,Moh JH,Choi YH,etc.A prodrug approach to COX-2 inhibitors with methylsulfone.[J].2004,14(7).
[13]Tsuji F.,Horiuchi M.,Okahara A.,etc.Involvement of leukotriene B-4 in arthritis models[J].1998,64(3).
[14]Schulze-Elfringhoff A,Lehr M,Hess M.1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A(2)alpha: Bioisosteric replacement of the carboxylic acid and carboxamide moiety.[J].2007,15(8).
[15]Djuric SW,Malecha JW,Askonas LJ,etc.Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene a(4) hydrolase.[J].2003,13(6).
[16]Bolognesi ML,Minarini A,Rosini M,etc.From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease.[J].2008,8(10).
[17]Haydn G. Beaton,Colin Bennion,Stephen Connolly,etc.Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2[J].1994,37(5).
[18]K M, Tramposch,S A, Steiner,P L, Stanley,etc.Novel inhibitor of phospholipase A2 with topical anti-inflammatory activity.[J].1992,189(1).
[19]Selchau V,Liang A,Chen M,etc.Synthesis of N-alkyl glycine amides as potent inhibitors of leukotriene A4 hydrolase.[J].2008,18(14).
[20]S E, Wenzel,A K, Kamada.Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.[J].1900,30(7-8).
[21]B, Lehnigk,K F, Rabe,G, Dent,etc.Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.[J].1998,11.
[22]Seiji Iwama,Masaki Segawa,Shinobu Fujii,etc.Design and synthesis of new secretory phospholipase A2 inhibitor of a phospholipid analog[J].1998,8(24).
[23]Wei P,Fang C,Zhou L,etc.Chemically induced dimerization of human nonpancreatic secretory phospholipase A2 by bis-indole derivatives[J].2008,51(12).
[24]Ss-Kic V,Schrattenholz A.What does systems biology mean for drug development?[J].2008,15(15).
[25]Draheim SE.,Hartley LW.,Clawson DK.,etc.Structure-Based Design of the First Potent and Selective Inhibitor of Human Non-Pancreatic Secretory Phospholipase a(2)[J].1995,2(6).
[26]Csermely P.Strong links are important, but weak links stabilize them[J].2004,29(7).
[27]Chen J,Lai LH.Pocket v.2: Further developments on receptor-based pharmacophore modeling[J].2006,46(6).
[28]Peter Vadas,John B. Hay.Secretion of a Hyperemia-Inducing Moiety by Mitogen or Glycogen Stimulated Mononuclear Inflammatory Cells of Sheep and Rabbit[J].1980,62(2).
[29]Csermely P,Agoston V,Pongor S.The efficiency of multi-target drugs: the network approach might help drug design.[J].2005,26(4).
[30]Bannwarth B.Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?[J].2004,18(1).
[31]Leval X,Julemont F,Delarge J,etc.New trends in dual 5-LOX/COX inhibition.[J].2002,9(9).
[32]Ian P. Street,Hung Kuei Lin,France Laliberte,etc.Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2[J].1993,32(23).
[33]Lehr M,Elfringhoff AS,Klimt M.Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2).[J].2001,11(19).
[34]Savall BM,Tays KL,Wei J,etc.Identification of a potent, selective, and orally active leukotriene A(4) hydrolase inhibitor with anti-inflammatory activity[J].2008,51(14).
[35]Samuelsson B,Morgenstern R,Jakobsson PJ.Membrane prostaglandin E synthase-1: a novel therapeutic target.[J].2007,59(3).
[36]Daniel Delorme,Yves Ducharme,Christine Brideau,etc.Dioxabicyclooctanyl Naphthalenenitriles as Nonredox 5-Lipoxygenase Inhibitors: Structure-Activity Relationship Study Directed toward the Improvement of Metabolic Stability[J].1996,39(20).
[37]C N, Serhan.Preventing injury from within, using selective cPLA2 inhibitors.[J].2000,1(1).
[38]Methot N,Rowland SE,Xu D,etc.MF63 (2-(6-chloro-1H-phenanthro(9,10-d)imidazol-2-yl)-isophthalonitrile), a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.[J].2008,326(3).
[39]G C, Crawley,R I, Dowell,P N, Edwards,etc.Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.[J].1992,35(14).
[40]Ronald A. LeMahieu,Mathew Carson,Ru Jen Han,etc.N-(Carboxymethyl)-N-[3,5-bis(decyloxy)phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity[J].1993,36(20).
[41]Kun, Yang,Hongjun, Bai,Qi, Ouyang,etc.Finding multiple target optimal intervention in disease-related molecular network.[J].2008,4.
[42]Mckew JC,Lee KL,Shen MWH,etc.Indole cytosolic phospholipase A(2) alpha inhibitors: Discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib[J].2008,51(12).
[43]A W, Ford-Hutchinson,M, Gresser,R N, Young.5-Lipoxygenase.[J].1994,63.
[44]M, Lehr.Synthesis, biological evaluation, and structure-activity relationships of 3-acylindole-2-carboxylic acids as inhibitors of the cytosolic phospholipase A2.[J].1997,40.
[45]T, Kolasa,C D, Brooks,K E, Rodriques,etc.Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.[J].1997,40(5).
[46]Giordano S,Petrelli A.From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.[J].2008,15(5).
[47]Morphy R,Rankovic Z.Fragments, network biology and designing multiple ligands.[J].2007,12(3/4).
[48]Fiebich B,Ulbrich H,Dannhardt G.Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type.[J].2002,37(12).
[49]de Gaetano G,Cerletti C,Donati MB.Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.[J].2003,24(5).
[50]Wei DG,Jiang XL,Zhou L,etc.Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching[J].2008,51(24).
[51]Lehr M,Bovens S,Ludwig J,etc.Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A(2)alpha[J].2006,49(8).